PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
arcticnovartis
Sun, 10/19/2025 – 16:34
Read more about PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
…
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population
arcticnovartis
Fri, 10/17/2025 – 14:04
Read more about Novartis Kisqali® 5-year NATALEE data demonstrate 2…
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population
arcticnovartis
Fri, 10/17/2025 – 14:04
Read more about Novartis Kisqali® 5-year NATALEE data demonstrate 2…
Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML
arcticnovartis
Fri, 10/17/2025 – 12:49
Read more about Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly …
Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML
arcticnovartis
Fri, 10/17/2025 – 12:49
Read more about Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly …
Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML
arcticnovartis
Fri, 10/17/2025 – 12:49
Read more about Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly …
Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)
arcticnovartis
Thu, 10/16/2025 – 07:19
Read more about Novartis Fabhalta® (iptacopan) meets Phase III primary e…
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
arcticnovartis
Tue, 09/30/2025 – 22:19
Read more about Novartis receives FDA approval for Rhapsido® (remibr…
Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US
arcticnovartis
Mon, 09/29/2025 – 14:19
Read more about Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US
…
Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US
arcticnovartis
Mon, 09/29/2025 – 14:19
Read more about Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US
…
